Buscar
ADC Therapeutics SA
ADCTAñadir a la lista de seguimiento
1.190USD
+0.065+5.70%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
151.33MCap. mercado
PérdidaP/E TTM
Más Datos de ADC Therapeutics SA Compañía
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Información de ADC Therapeutics SA
Símbolo de cotizaciónADCT
Nombre de la empresaADC Therapeutics SA
Fecha de salida a bolsaMay 15, 2020
Director ejecutivoMallik (Ameet)
Número de empleados263
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 15
DirecciónBiopole
CiudadEPALINGES
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísSwitzerland
Código postal1066
Teléfono41216530200
Sitio Webhttps://adctherapeutics.com/
Símbolo de cotizaciónADCT
Fecha de salida a bolsaMay 15, 2020
Director ejecutivoMallik (Ameet)
Ejecutivos de ADC Therapeutics SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
2.35M
+10.02%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
943.88K
+8.69%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
695.69K
+14.14%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
581.57K
+1.47%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
222.99K
+19.21%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
177.38K
+23.91%
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
131.80K
+24.58%
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
95.41K
+33.96%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Director
Director
72.40K
+44.75%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
2.35M
+10.02%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
943.88K
+8.69%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
695.69K
+14.14%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
581.57K
+1.47%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
222.99K
+19.21%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de ADC Therapeutics SA?
Los cinco principales accionistas de ADC Therapeutics SA son: Mr. Ameet Mallik
¿Cuántas instituciones poseen acciones de ADC Therapeutics SA (ADCT)?
A fecha de 2026Q1, 205 instituciones poseen acciones de ADC Therapeutics SA, con un valor de mercado combinado de aproximadamente 87.78M, lo que representa el 69.09% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1768527.00.
¿Cuál es la mayor fuente de ganancias de ADC Therapeutics SA?
El 2026Q1, el segmento empresarial Product generó la ganancia más alta para ADC Therapeutics SA, ascendiendo a 73.55M y representando el 90.41% de la ganancia total.